Engineered immune cells take on Drug-Resistant lung cancer in first human trial

NCT ID NCT06097962

Recruiting now Disease control Sponsor: Base Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost the immune system's attack on tumors. Participants receive the cells either through a vein or directly into the chest cavity if they have fluid buildup. The main goals are to check safety and see if tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma Pleural Effusion, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jinling hospital, affiliated to Medical school Nanjing University
RECRUITING

Nanjing, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••